XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as part of Multi-Product Rollout Strategy
Vancouver, Canada, and Uttenweiler, Germany (February 1, 2022) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the execution of Covid-ID Lab sales contracts with both digitallifecare Corona Testzentren (“digitallife”), powered by digitallifecare GmbH, Germany and a group of pharmacies in Bamberg, Germany.
Digitallife operates five coronavirus test centers south of Stuttgart, Germany, servicing a local community of approximately 75,000. Personnel training and equipment installation were completed last week and the first order of test kits has been delivered. In addition to testing for the general public, digitallife will also service corporate clients in the region with COVID-ID Lab PCR testing.
The Company also commenced selling to pharmacies in Bamberg, Germany servicing a local community of approximately 78,000.
The Company expects to advance and execute additional sales contracts and will release details as they become available.
“Having recently joined the Company to lead global marketing and sales initiatives, I am extremely pleased to announce today’s contracts,” said Roland Spleiss, Director of Business Development. “This is just one of many direct sales engagements that we currently pursuing in Germany, which are in addition to a number of European and global distribution agreements that are under review. It is a consequence of the joint efforts of both 3a and Vektor staff, providing training capacities at a high level.”
Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of the sample preparation. The RT-PCR sample process detects the SARS-CoV-2 virus on a test chip within 5 minutes, when SARS-CoV-2 is present, the result can be read visually immediately. The target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.
The Company is pleased to have recently embarked on a process of rapid management change with a focus on product commercialization and sales. The company has a development pipeline of additional medical and oral health products that will be continuously rolled out with the commercialization team gaining rapid traction and momentum. News on the product rollout strategies will be released in due course.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.